<DOC>
	<DOC>NCT02254629</DOC>
	<brief_summary>the laxative-probiotic sequential treatment might reduce the symptoms of IBS and alter the fecal microbiota of the patients in a more robust manner .</brief_summary>
	<brief_title>The Effects of Laxative-probiotic Sequential Treatment in the Irritable Bowel Syndrome Patients</brief_title>
	<detailed_description>Probiotics can regulate intestinal immunity, repair mucosal barrier, and reportedly exert therapeutic effects on IBS patients. The laxatives could also alter the gut microflora significantly, thus the laxative-probiotic sequential treatment might affect the symptoms and the composition of fecal microbiota in the IBS patients in a more robust manner .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Laxatives</mesh_term>
	<mesh_term>Cathartics</mesh_term>
	<criteria>the presence of Rome III criteria for IBS ; Patients scheduled for colonoscopy examination or having negative screening examinations Aged between 18 and 65 years old Antibiotic, probiotic or laxative usage within 4 weeks. organic gastrointestinal diseases Severe systematic disease: diabetes mellitus, hepatic, renal or cardiac dysfunction, thyroid disease or tumor etc. pregnancy or lactation. previous major or complicated abdominal surgery. severe endometriosis and dementia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Fecal microflora</keyword>
	<keyword>IBS</keyword>
	<keyword>Sequential treatment</keyword>
	<keyword>Probiotic</keyword>
	<keyword>Laxative</keyword>
</DOC>